Semaglutide, a glucagon-like peptide-1 analog for the once-weekly treatment of type 2 diabetes, provided superior glycemic control and weight loss (WL) vs. comparators in the SUSTAIN clinical trial program. This post hoc analysis assessed if WL was associated with patient-reported health-related quality of life (HRQoL) and treatment satisfaction improvements in SUSTAIN 2-5 and 7. Data for both semaglutide doses (0.5 and 1.0 mg) were pooled across trials (N=2,808). Change in HRQoL (Short Form-36 Health Survey version 2® [SF-36v2®] Physical Component Summary [PCS] and Mental Component Summary) and treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire status version) scores were evaluated in subjects who achieved ≥5% and ≥10% WL vs. those who did not at end of treatment (30, 40 or 56 weeks). Overall, 51.0% and 17.4% of subjects achieved ≥5% and ≥10% WL with semaglutide. Significantly greater improvements in the overall PCS score and most of its components were reported in subjects achieving ≥5% and ≥10% WL vs. those not achieving these responses (Table). WL responses also correlated with overall treatment satisfaction and perception of hyperglycemia (Table).

In conclusion, semaglutide-induced WL was associated with improvements in PCS domains of the SF-36v2®, overall treatment satisfaction and perception of hyperglycemia across the SUSTAIN 2-5 and 7 trials.
graphic
View largeDownload slide
Disclosure

K.T. Uusinarkaus: Advisory Panel; Self; AstraZeneca, Janssen Pharmaceuticals, Inc., Novo Nordisk Inc. Speaker's Bureau; Self; Amarin Corporation, Amgen Inc., Regeneron Pharmaceuticals, Sanofi US. Stock/Shareholder; Self; Abbott, AbbVie Inc., Amarin Corporation, Pfizer Inc. H.W. Rodbard: Advisory Panel; Self; Bayer US, Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc., Sanofi. Consultant; Spouse/Partner; Eli Lilly and Company. Consultant; Self; Gan & Lee Pharmaceuticals. Research Support; Self; Lexicon Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi. Speaker's Bureau; Self; Merck & Co., Inc., Novo Nordisk Inc. L. Van Gaal: Advisory Panel; Self; Janssen Pharmaceuticals, Inc., Johnson & Johnson. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi, Servier. J.P. Wilding: Consultant; Self; Astellas Pharma Europe Ltd., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, NAPP Pharmaceuticals Limited, Novo Nordisk A/S, Sanofi. Research Support; Self; AstraZeneca, Novo Nordisk A/S. Speaker's Bureau; Self; Eli Lilly and Company, WebMD. T. Hansen: None. A. Sandberg: Employee; Self; Novo Nordisk A/S. S. Tadayon: Employee; Self; Novo Nordisk A/S. M.J. Davies: Advisory Panel; Self; Eli Lilly and Company, Janssen Global Services, LLC., Novo Nordisk A/S, Sanofi-Aventis, Servier. Research Support; Self; Boehringer Ingelheim International GmbH, Novo Nordisk Foundation. Speaker's Bureau; Self; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk A/S, Sanofi-Aventis, Takeda Pharmaceutical Company Limited.

Funding

Novo Nordisk A/S

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.